Novo's CagriSema Delivers Superior Weight Loss Vs Tirzepatide In REIMAGINE 5 Trial
READ HERE
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
3 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
NVO Novo Nordisk LLY Eli Lilly: CagriSema Delivers Superior Weight Loss vs. Tirzepatide in REIMAGINE 5 ⠀ · CagriSema patients lost 12.4% of body weight at Week 60 vs. 9.1% with tirzepatide. · Trial used a 1.0 mg dose of each CagriSema component.
NVO Novo Nordisk LLY Eli Lilly: CagriSema Delivers Superior Weight Loss vs. Tirzepatide in REIMAGINE 5 ⠀ • CagriSema patients lost 12.4% of body weight at Week 60 vs. 9.1% with tirzepatide. • Trial used a 1.0 mg dose of each CagriSema component.
Novo's Cagrisema Delivers Superior Weight Loss Versus Tirzepatide In Reimagine 5 Trial
Cagrisema 1.0 Mg/1.0 Mg Achieves 12.4% Weight Loss Vs 9.1% Tirzepatide At Week 60 Cagrisema 1.0 Mg/1.0 Mg Confirms Non-Inferior Hba(1c) Reduction Of 1.71% Vs 1.67% Tirzepatide Cagrisema Shows Greater Improvements Than Placebo In Multiple Supportive Endpoints